KDR and pachyonychia congenita: Recently, new targeted drugs for GC have emerged, including monoclonal antibodies against VEGF, the VEGF receptor (VEGFR), and HER-2, and mammalian target of rapamycin (mTOR) inhibitors; however, no breakthrough has been achieved in treating advanced GC, associated or not with PC [15].